As­traZeneca snaps up ra­dio­phar­ma part­ner for $2B up­front

As­traZeneca is bet­ting $2 bil­lion up­front to buy Fu­sion Phar­ma­ceu­ti­cals, join­ing a land grab in the bur­geon­ing ra­dio­phar­ma­ceu­ti­cals space.

The deal, which al­so in­cludes up …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER